Xenon Pharmaceuticals (NASDAQ:XENE) Earns Overweight Rating from Analysts at Wells Fargo & Company
Wells Fargo & Company began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $48.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts have also recently weighed in on XENE. […]
More Stories
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
Global Trade in 2026: AI Investment Is Rewriting the Map of World Commerce By Looking Times | November 13, 2026...
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
The AI Investment Boom: Can Record Spending Deliver Real Productivity? By Looking Times | November 13, 2026 Image: Derrick Coetzee,...
Global Trade in 2026: How AI Is Reshaping the World Economy
Global shipping remains a vital link in international trade. Image: Wilfredor, Wikimedia Commons, CC0 1.0 (public domain dedication). Image source...
How to Eliminate Bottlenecks in Cross-Team Workflows
A business is often made of different teams. These teams need to work together. However, things don’t always go as...
Global Economy and International Trade: How the World Is Building a More Connected but Uncertain Future
The global economy is entering a new era of transformation as international trade, technological innovation and geopolitical tensions reshape relationships...
54,000 Bankruptcies Filed in October, Report Says
By Naveen Athrappully A total of 54,028 bankruptcy filings were made in October, a 2 percent jump from a year...